Sengupta et al., showed that pharmacologic inhibition of GSK3 with SB216763 in glioblastoma (GBM)-specific CAR T cells can reduce the expression of Fas ligand (FasL) and exhaustion marker [e.g., programmed cell death protein 1(PD-1)] and increase T cell proliferation resulting in the development of CAR T effector memory phenotype (61). This evidence concerns the gene PDCD1 and glioblastoma.